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Abstract 
Cyclin dependent kinase-5 (cdk5)/p35 is a neuronal kinase that regulates key 
axonal and synaptic functions but the mechanisms by which it is transported 
to these locations are unknown. Lemur tyrosine kinase-2 (LMTK2) is a binding 
partner for p35 and here we show that LMTK2 also interacts with kinesin-1 
light chains (KLC1/2). Binding to KLC1/2 involves a C-terminal 
tryptophan/aspartate (WD) motif in LMTK2 and the tetratricopeptide repeat 
(TPR) domains in KLC1/2, and this interaction facilitates axonal transport of 
LMTK2. Thus, siRNA loss of KLC1 or mutation of the WD motif disrupts 
axonal transport of LMTK2. We also show that LMTK2 facilitates the formation 
of a complex containing KLC1 and p35 and that siRNA loss of LMTK2 
disrupts axonal transport of both p35 and cdk5. Finally, we show that LMTK2 
levels are reduced in Alzheimer’s disease brains. Damage to axonal transport 
and altered cdk5/p35 are pathogenic features of Alzheimer’s disease. Thus, 
LMTK2 binds to KLC1 to direct axonal transport of p35 and its loss may 
contribute to Alzheimer’s disease. 
 
Key Words: Lemur tyrosine kinase-2, kinesin-1, cyclin dependent kinase-
5/p35; axonal transport, Alzheimer’s disease.  
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Introduction 
Dynamic changes to protein phosphorylation underpin many aspects of 
neuronal function. p35 is a binding partner and activator subunit of the 
neuronal serine-threonine kinase cdk5 [7, 23, 43, 47]. Together with cdk5, p35 
regulates a variety of fundamental physiological processes within neurons 
including synaptic vesicle trafficking, dopaminergic and glutaminergic 
signalling, and axonal functions involving axonal outgrowth and the regulation 
of transport of cargoes through axons (axonal transport) [1, 7, 20, 36, 43]. In 
addition, damage to p35 leading to altered cdk5/p35 activity is believed to 
contribute to the pathogenesis of Alzheimer’s disease [7, 41, 43]. Despite the 
major roles that p35 plays within axons and synapses, the mechanisms by 
which it is transported into and through axons to these locations are unknown. 
Understanding these mechanisms is essential for properly comprehending 
p35 and cdk5 function in neurons and also its dysfunction in Alzheimer’s 
disease. 
 
In addition to binding cdk5, p35 also binds to LMTK2 (also known as brain-
enriched kinase, apoptosis-associated tyrosine kinase-2, 
kinase/phosphatase/inhibitor-2, cdk5/p35 regulated kinase, lemur tail kinase-2 
and KIAA1079) [18, 28]. LMTK2 is a member of the lemur family of kinases 
which are a structurally unique group of kinases that are anchored in the 
membrane by a membrane-spanning region located at their extreme N-termini 
and which contain an N-terminally located kinase domain with a long C-
terminal “tail” [3, 17, 18, 46, 53, 56]. As such, they have been named after 
lemurs, the long-tailed Madagascan primates. Topography studies have 
confirmed earlier predictions that LMTK2 is orientated so that its C-terminal 
tail projects into the cytosol [37]. Although originally predicted to be a dual-
specificity serine-threonine/tyrosine kinase, several studies have since shown 
that LMTK2 only targets serine and threonine residues [17, 27, 28, 53, 54]. In 
neurons, LMTK2 along with p35 is enriched in cell bodies and the Golgi but is 
also present in axons and axon termini [18]. 
 
Kinesin-1 is a major microtubule-associated molecular motor that mediates 
transport of a wide variety of cargoes within neurons [13]. In axons, 
microtubule orientation is nearly uniform with the plus ends pointing toward 
the synapse and the minus ends facing the cell body. Since kinesin-1 
unidirectionally moves toward microtubule plus ends, in axons it mostly drives 
anterograde transport toward the synapse. A proportion of functional kinesin-1 
comprises a hetero-tetramer of two kinesin-1 motor proteins and two kinesin-1 
light chains; KLC1 and KLC2 are the best characterized light chains [13, 31]. 
Kinesin-1 contains ATPase activity and uses the chemical energy of ATP to 
drive conformational changes that generate motile force; in contrast, the KLCs 
are mainly involved in binding of cargoes.  
 
The importance of kinesin-1 driven axonal transport suggests that any 
disruption to this process may be detrimental to neurons. Indeed, damage to 
axonal transport is strongly implicated in Alzheimer’s disease [2, 5, 9, 30, 55]. 
Here we show that LMTK2 interacts with KLC1/2 and that this interaction 
facilitates its anterograde transport through axons. We also show that LMTK2 
mediates the formation of a complex containing KLC1 and p35 and that 
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siRNA loss of LMTK2 disrupts axonal transport of both p35 and cdk5. Finally, 
we show that LMTK2 levels are reduced in affected regions in post mortem 
Alzheimer’s disease brains. Loss of LMTK2 may therefore contribute to 
Alzheimer’s disease by effects on axonal transport of p35 and cdk5. 
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Materials and Methods 
Plasmids and siRNAs 
pCI-neo control empty vector was from Promega. Myc-tagged mouse LMTK2, 
FLAG-tagged mouse KLC1 and KLC2, hemagglutinin (HA)-tagged human 
cdk5 and HA-, EGFP- and DsRed-tagged p35 plasmids were as described 
previously [12, 27, 51, 58]. C-terminal EGFP-tagged LMTK2 was generated 
by PCR amplification of LMTK2 [27] so as to remove the stop codon and 
cloning into pEGFP-N1 (Clontech) as a XhoI-HindIII fragment. Primers were 
5’-AAACTCGAGATGCCGGGGCCGCCGGCG-3’ and 5’-
AAAAAGCTTCTAGTCCTTGTCTCCGTCTTCAC-3’. N-terminally myc-tagged 
mouse kinesin-1A was generated by PCR from kinesin-1A IMAGE clone 
(BC058396; GeneService) and cloning into pCI-neo as a NheI-NheI fragment. 
Primers were 5’-
AAAGCTAGCGAACAAAAACTCATCTCAGAAGAGGATCTGATGGCGGAGA
CTAACAACGAA -3’ and 5’-AAAGCTAGCTTAGCTGGCTGCTGTCTCTT-3’. 
N-terminal EGFP-tagged cdk5 was generated by subcloning HA-cdk5 into 
pEGFP-C1 (Clontech) as a BamHI-BamHI fragment. Mutant proteins were 
generated using a QuikChange II XL site-directed mutagenesis kit (Agilent 
Technologies) according to the manufacturer’s instructions with the following 
primer pairs: 
LMTK2(WE477/478AA) 5’-
AGCTTTGAGTATGTGGCGGCGGCTGCCAAGCACGAC-3’ and 5’-
GTCGTGCTTGGCAGCCGCCGCCACATACTCAAAGC-3’ 
LMTK2(WD1388/1389AA) 5’-
GGCGGAGGCTTTGAAGCGGCCGATGACTTCTCCCCG-3’ and 5’-
CGGGGAGAAGTCATCGGCCGCTTCAAAGCCTCCGCC-3’ 
KLC1(N302L) 5’-GGCAGCGACTCTGAACCTCCTAGCAGTACTGTACGG-3’ 
and 5’-CCGTACAGTACTGCTAGGAGGTTCAGAGTCGCTGCC-3’ 
KLC2(N287L) 5’-GGCTGCGACCCTCAACCTTCTGGCTGTTCTCTACGGC-3’ 
and 5’-GCCGTAGAGAACAGCCAGAAGGTTGAGGGTCGCAGCC-3’  
All constructs were verified by sequencing. 
 
LMTK2, KLC1 and control siRNAs (Accell range) were from Dharmacon 
Horizon Discovery. LMTK2 siRNA was a pool of four constructs: 5’-
GCCUGAGCUUUGAGUACGU-3’, 5’-CCCUUGGGUUUGUUGAAUU-3’, 5’-
GUGUGCAGUUUAAUGGUAC-3’ and 5’-GAAAUAGACUUUAAGGAAU-3’. 
KLC1 siRNA was 5’-GGGUCGUCUUUUGGAGAGU-3’. 
 
Antibodies 
The following primary antibodies were used in this study:  
rabbit anti-cdk5 (C-8, Santa Cruz; 1/500 immunoblot (IB)), mouse anti-FLAG 
(M2, Sigma; 1/250 immunoprecipitation (IP), 1/2000 IB), rabbit anti-GFP 
(Abcam; 1/250 IP; 1/5000 IB), mouse anti-GFP (B-2, Santa Cruz; 1/1000 IB), 
rabbit anti-HA (Sigma; 1/2000 IB; 1/500 immunofluorescence (IF)), mouse 
anti-kinesin-1 (H2, Millipore; 1/3000 IB), rabbit anti-KLC1 (H-75, Santa Cruz; 
1/2000 IB), goat anti-KLC1 (L-15, Santa Cruz; 1/100 PLA), rabbit anti-LMTK2 
(ab24782 Abcam; 1/500 IB), rabbit anti-LMTK2 (EPR7836(2); Abcam; 1/500 
IB), rabbit anti-LMTK2 (described previously [18] 1/100 PLA), mouse anti-myc 
(9B11, Cell Signaling; 1/250 IP; 1/2000 IB; 1/2000 IF), mouse anti neuron 
specific enolase (NSE; Dako; 1/50,000 IB), rabbit anti-p35 (C-19, Santa Cruz; 
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1/100 PLA), rabbit-anti p35/25 (C64B10; Cell Signaling; 1/2000 IB), mouse 
anti-tubulin (DM1A, Sigma; 1/20,000 IB), mouse anti-β-tubulin isotype III 
(SDL.3D10; Sigma; 1/500 IF). 
 
Cell culture and transfection 
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium with 4.5 g/l 
glucose (GE Healthcare) supplemented with 10% (v/v) fetal bovine serum and 
2 mM L-glutamine. Cells were transfected using TurboFect (Thermo 
Scientific) or with polyethylenimine MAX (Polysciences) according to the 
manufacturer’s instructions. Cells were analysed 24 h post-transfection. 
 
Rat cortical neurons were obtained from embryonic day 17 embryos, plated 
on poly-L-lysine coated 18 mm diameter glass coverslips (Marienfield GmbH 
& Co.KG) or on 35 mm diameter glass bottom P-dishes (Ibidi GmbH) and 
cultured in Neurobasal medium containing B27 supplement (Invitrogen), 2 mM 
L-glutamine, 100 IU/ml penicillin and 100 Pg/ml streptomycin. Neurons were 
transfected using Lipofectamine 2000 (Invitrogen) (2 Pl/Pg DNA in Opti-MEM) 
according to the manufacturer’s instructions and analysed 24 h post 
transfection on DIV6 or 7. siRNAs were applied at DIV2 for 96 h.  
 
SDS-PAGE and immunoblotting 
Cells were harvested for SDS-PAGE and immunoblotting by scraping into 
SDS-PAGE sample buffer containing 2% (w/v) SDS, 100 mM dithiothreitol, 
10% (w/v) glycerol, 0.1% (w/v) bromophenol blue and protease inhibitors 
(Complete Roche) in 50 mM Tris-HCl pH 6.8 and heating to 96 °C for 5 min. 
Other samples were prepared by addition of SDS-PAGE sample buffer and 
heating to 100 °C for 5 min. Samples from cell cultures were separated on 8 
or 12% gels using Mini-PROTEAN 3 gel electrophoresis systems (Bio-Rad) 
with a discontinuous buffer system. Human post-mortem brain homogenates 
were separated on Novex 4-12% Tris-Glycine Plus Midi Protein gels 
(Invitrogen) using the XCell4 Sureloc Midi-Cell system (Invitrogen). Separated 
proteins were transferred to BioTrace NT nitrocellulose membrane (0.2 Pm 
pore size; Pall Corporation) using a Mini Trans-Blot electrophoretic transfer 
cell (Bio-Rad) for 16 h or a Midi Trans-Blot electrophoretic transfer cell (Bio-
Rad) for 2 h. Membranes were blocked with Tris-HCl buffered saline (TBS) 
containing 5% (w/v) milk powder and 0.1% (w/v) Tween-20 for 1 h or with 
Odyssey TBS blocking buffer (Li-Cor Biosciences) for 1h. Membranes were 
probed with primary antibodies in blocking buffers supplemented with 0.1% 
(w/v) Tween-20 (TBS/Tween-20), washed in TBS/Tween-20 and incubated 
with horseradish peroxidase (HRP)-conjugated secondary antibodies in wash 
buffer, and developed using an enhanced chemiluminescence development 
reagent (GE Healthcare) and exposure on Hyperfilm ECL. Alternatively, blots 
were incubated with IRDye-conjugated secondary antibodies in wash buffer 
and proteins visualised using an Odyssey CLx near infrared imaging system 
(Li-Cor Biosciences).  
 
Signals on Hyperfilm ECL developed immunoblots were quantified using 
ImageJ (version 1.50b; developed by Wayne Rasband, National Institute of 
Health, Bethesda, USA) after scanning with an Epson Precision V700 Photo 
scanner as described by us in earlier studies [34]; only signals within the 
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linear optical density range were used for analyses. Signals obtained with 
Odyssey CLx imaging system were quantified by Image Studio Lite (version 
5.2.5; Li-Cor Biosciences). LMTK2 signals obtained from human brain 
samples were normalised to NSE signals from the same membrane. 
 
Immunoprecipitation assays 
Immunoprecipitation assays were performed essentially as described [34]. 
Briefly, cells were washed with phosphate buffered saline (PBS) and 
harvested by scraping into ice-cold immunoprecipitation lysis buffer (50 mM 
Tris-citrate pH 7.4; 150 mM NaCl; 1% (v/v) Triton X-100; 5 mM EGTA; 5 mM 
EDTA and protease inhibitors (Complete, Roche)) for 1 h. Following 
centrifugation at 15,000 x g for 30 min at 4 ºC, samples were incubated with 
primary antibody for 16 h at 4 ºC. Antibodies were captured using Protein G-
sepharose beads (50% (v/v) in PBS supplemented with 0.1% (v/v) Triton X-
100) for 2 h at 4 ºC, washed in capture buffer and bound proteins eluted and 
prepared for SDS-PAGE by incubation in 50 Pl SDS-PAGE sample buffer and 
heating at 96 ºC for 5 min. 
 
Preparation of human brain samples for SDS-PAGE and immunoblotting 
Post-mortem human frontal cortex and cerebellum samples from control and 
pathologically confirmed cases of Alzheimer’s disease were obtained from the 
Medical Research Council Neurodegenerative Diseases Brain Bank, King’s 
College London. All tissue collection and processing were carried out under 
the regulations and licensing of the Human Tissue Authority, and in 
accordance with the Human Tissue Act, 2004. Post mortem studies from 
some control, clinically non-demented individuals revealed early Braak stage 
pathologies. Frozen human brain tissues were prepared as 20% 
homogenates in ice-cold radioimmunoprecipitation assay (RIPA) buffer (50 
mM Tris-HCl, pH 7.4; 150 mM NaCl; 1 mM EDTA; 1% (v/v) Triton X-100; 
0.5% (w/v) sodium deoxycholate; 0.1% (w/v) SDS) with protease and 
phosphatase inhibitor cocktails (Roche) using a Bio-Gen PRO200 rotor-stator 
homogeniser (Pro Scientific) for 20 s. Following homogenisation, each sample 
was sonicated three times for 3 s before being centrifuged at 13,000 x g for 20 
minutes at 4 qC. Supernatants were collected and protein concentrations 
determined using a bicinchoninic acid protein concentration assay kit (Pierce) 
according to the manufacturer’s instructions. Protein concentrations were 
adjusted to the same concentration in each sample by adding RIPA and SDS-
PAGE sample buffers. Samples were stored at -80 qC and heated to 96 qC for 
10 minutes prior to SDS-PAGE. 
 
Immunofluorescence microscopy 
Cells were fixed in 4% (w/v) paraformaldehyde in PBS for 15 min, washed 
three times in PBS, quenched with 50 mM NH4Cl in PBS for 15 min and 
permeabilised with 0.2% (v/v) Triton X-100 in PBS for 3 min. Cells were 
blocked with 3% (w/v) bovine serum albumin in PBS for 30 min and incubated 
with primary antibodies in blocking solution for 1 h. Following washing with 
PBS, the primary antibodies were detected using donkey anti-mouse Igs 
coupled with Cy5 (Jackson Immuno Research), goat anti-mouse and anti-
rabbit Igs coupled with AlexaFluor 488, or 546 (Invitrogen) in blocking 
solution. After washing in PBS the samples were mounted in fluorescence 
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 8 
mounting medium (Dako) or Mowiol-DABCO containing 10% (w/v) Mowiol 4–
88 (Calbiochem), 25% (w/v) glycerol and 1% (w/v) DABCO (1,4-
diazobicyclo[2.2.2]octane) in 100 mM Tris–HCl pH 8.5. 
 
Images were captured using a Leica DM5000 B microscope equipped with 
40x/0.75NA HCX-PL-FLUOTAR objective, DFC360 FX camera and 
appropriate filter sets (Leica). Axonal LMTK2, p35 and cdk5 levels were each 
acquired using the same microscope settings and quantified using ImageJ. To 
do so, background corrected non-saturated fluorescent axonal and cell body 
density signals were acquired and each axonal signal then normalised to its 
corresponding cell body signal. 
 
Proximity ligation assays 
Proximity ligation assays (PLAs) were performed with rabbit anti-LMTK2 and 
goat anti-KLC1, and with rabbit anti-p35 and goat anti-KLC1 antibodies using 
Duolink PLA probes and orange detection reagent (Sigma) according the 
manufacturer’s protocol. Briefly, cells were fixed and permeabilised as 
described above for immunofluorescence staining, blocked with PLA blocking 
buffer for 30 min at 37°C and incubated with primary antibodies for 1 h. 
Following washing, samples were incubated with PLA probes for 1 h at 37°C 
and after further washing, probes were ligated for 30 min at 37 °C and 
amplified for 100 min at 37 °C. Following PLAs, cells were incubated with 
tubulin primary antibody in PBS at 4 °C for 16 h, washed with PBS and 
incubated with fluorescent conjugated secondary antibody for 1 h in PBS. 
Following further washing, samples were mounted as described above. 
Control reactions to demonstrate the specificity of the assays involved 
omission of primary antibodies. Signals were quantified using ImageJ particle 
analysis function as described [42]. 
 
Time-lapse microscopy 
Axonal transport of EGFP- and DsRed-tagged LMTK2, p35 and cdk5 in living 
neurons was monitored using a Nikon Eclipse Ti-E microscope equipped with 
Intenslight C-HGFI light source (Nikon), EGFP and DsRed filter sets (Chroma 
Technology), CFI Apo Lambda S 60x/1.40 objective (Nikon) and an Andor 
Neo scientific complementary metal-oxide-semiconductor camera (Andor 
Technology). Movements were recorded using NIS-Elements AR software 
(Nikon). Particles were imaged 24-36 h post-transfection in Ibidi P-dishes or 
by mounting coverslips in a Ludin imaging chamber (Life Imaging Services) 
filled with external solution (145 mM NaCl, 2 mM KCl, 5 mM NaHCO3,1 mM 
MgCl2, 2.5 mM CaCl2,10 mM glucose in 10 mM HEPES pH 7.0). Temperature 
was maintained at 37 °C during imaging using a microscope incubation 
chamber (Solent Scientific). Movements were recorded at 1 s time-lapse 
intervals and 100 ms exposure times. Kymographs were created using the 
Straighten and Kymograph plugins of ImageJ. In line with our previous 
studies, we chose cells expressing low levels of transfected proteins (as 
judged by the fluorescent protein signal) for analyses so as to avoid any 
possible artefacts produced by high levels of expression [1, 50].  
 
Statistical analyses 
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 9 
Statistical analysis was performed using Excel (Microsoft Corporation), Prism 
software (version 7.02; GraphPad Software Inc.) and SPSS (version 24.0.0.1; 
IBM). Statistical significance was determined by t-test or analysis of variance 
(ANOVA) followed by post-hoc test as described in figure legends. Data are 
plotted as mean±s.e.m. All experiments were repeated at least three times. 
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Results 
LMTK2 binds to KLCs via a C-terminal WD motif 
We tested whether LMTK2 might bind to KLC1 and KLC2 in 
immunoprecipitation assays. To do so, we transfected HEK293 cells with 
either empty pCIneo control vector, myc-tagged LMTK2 (myc-LMTK2), FLAG-
tagged KLC1 (FLAG-KLC1), FLAG-KLC2, myc-LMTK2+FLAG-KLC1 or myc-
LMTK2+FLAG-KLC2 and monitored the LMTK2-KLC1/KLC2 interaction on 
immunoblots following immunoprecipitation of either LMTK2, KLC1 or KLC2 
via their epitope tags. LMTK2 bound to both KLC1 and KLC2 in these assays 
and the interaction was only detected in LMTK2+KLC1/KLC2 co-transfected 
cells which demonstrates the specificity of the assays (Figure 1a). 
 
The mechanisms by which cargoes attach to kinesin-1 motors are not fully 
understood but one route involves interactions between the tetratricopeptide 
repeat (TPR) domains in KLC1/2 and cargo located tryptophan-
aspartate/tryptophan-glutamate (WD/WE) motifs [10, 33, 40]. Mutation to 
leucine of conserved asparagines within the KLC TPRs (KLC1(N302) and 
KLC2(N287)) has been shown to disrupt WD/WE cargo binding [40, 59]. We 
therefore studied binding of LMTK2 to mutant KLC1(N302L) and 
KLC2(N287L) using immunoprecipitation assays similar to those described 
above. Mutant KLC1(N302L) did not bind and KLC2(N287L) displayed 
reduced binding to LMTK2 in these assays (Figure 1b, c). Differences in 
binding of WD/WE containing proteins to KLC1 and KLC2 have been 
described previously [10, 49]. 
 
LMTK2 contains two conserved WE/WD motifs that might potentially interact 
with the KLC TPR domains (WE477/478 and WD1388/1389). We therefore 
mutated LMTK2(WE477/478) and LMTK2(WD1388/1389) separately to 
double alanine, and again monitored binding of the mutants to KLC1 and 
KLC2 in immunoprecipitation assays. Mutant LMTK2(WE477/478AA) bound 
to both KLC1 and KLC2 in a manner indistinguishable from wild-type LMTK2 
(Figure 1d, e). However, mutant LMTK2(WD1388/1389AA) did not bind to 
KLC1 and displayed reduced binding to KLC2 (Figures 1d, e). These findings 
complement the above studies showing that mutation of the KLC1 TPR 
domain had a more potent effect on binding to LMTK2 than mutation of the 
KLC2 TPR domain (Figures 1b, c). We therefore focussed on the LMTK2-
KLC1 interaction. KLC1 has been shown to be involved in transporting a large 
number of cargoes in axons [11, 44, 52]. 
 
We next used immunoprecipitation assays to determine whether LMTK2 is 
complexed with the kinesin-1 motor. To do so, we immunoprecipitated EGFP-
tagged wild-type LMTK2 or LMTK2(WD1388/1389AA) from FLAG-
KLC1+myc-kinesin-1 co-transfected HEK293 cells. Both KLC1 and kinesin-1 
bound to LMTK2 but not LMTK2(WD1388/1389AA) in these assays (Figure 
2a). Finally, we used proximity ligation assays (PLAs) to test whether 
endogenous LMTK2 and KLC1 were associated with each other in cultured 
HEK293 cells and rat cortical neurons. These PLAs produced positive signals 
which in the neurons included in cell bodies and axons (Figure 2b, c). In both 
HEK293 cells and neurons, confocal analyses revealed that the KLC1-LMTK2 
PLA signals were particularly abundant in perinuclear regions but not within 
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nuclei. This is in agreement with previous studies which show that LMTK2 is 
enriched in these areas including the Golgi [18]. Thus, LMTK2 binds to both 
KLC1 and KLC2 via a conserved WD motif in its C-terminal tail domain 
(residues 1388/1389), this binding involves the KLC TPR domains and the 
interaction of LMTK2 with KLC1 facilitates its binding to the kinesin-1 motor 
complex. 
 
Axonal transport of LMTK2 involves its binding to KLC1 
LMTK2 is present in neuronal cell bodies and axons [18]. To determine 
whether LMTK2 delivery into axons involves its binding to KLCs, we first 
studied how siRNA depletion of KLC1 affected the axonal distribution of 
transfected myc-LMTK2 in rat cortical neurons. KLC1 siRNAs have been 
characterised previously [51] and induced an approximate 80% reduction in 
protein levels without affecting expression of endogenous kinesin-1, LMTK2, 
p35 or cdk5 (Supplementary Figure 1a). Neuronal morphologies were 
determined by co-transfection of DsRed and LMTK2 was identified by 
immunostaining for its myc-tag. Compared to untreated or control siRNA 
treated neurons, KLC1 siRNA knockdown cells displayed a noticeable 
reduction in axonal LMTK2 labelling. To quantify this phenotype, we 
normalised axonal LMTK2 fluorescent signals to cell body signals in each 
neuron. These analyses revealed a significant reduction in axonal LMTK2 in 
the KLC1 siRNA knockdown cells (Figure 3a). 
 
To complement these KLC1 siRNA knockdown studies, we also monitored 
axonal localisation of transfected wild-type myc-LMTK2 and mutant myc-
LMTK2(WD1388/1389AA) that does not bind to KLC1 in the cortical neurons. 
Compared to wild-type LMTK2, LMTK2(WD1388/1389AA) displayed reduced 
axonal labelling and we again quantified this phenotype by normalising axonal 
LMTK2 fluorescent signals to cell body signals in each neuron. These 
analyses confirmed that LMTK2(WD1388/1389AA) levels were significantly 
reduced in axons (Figure 3c). 
 
We next monitored how siRNA loss of KLC1 and mutation of 
LMTK2(WD1388/1389AA) affect axonal transport of transfected EGFP-
LMTK2 in living rat cortical neurons using time-lapse microscopy. Movement 
of wild-type EGFP-LMTK2 was observed in both anterograde and retrograde 
directions and the mean anterograde velocity was 0.58 +/- 0.42 Pm/s. This 
velocity for EGFP-LMTK2 movement is in line with the velocities described for 
other known kinesin-1/KLC1 cargoes such as calsyntenin-1, amyloid 
precursor protein (APP) and Kidins220/ARMS [4, 50, 51]. However, siRNA 
loss of KLC1 significantly reduced the numbers of anterogradely moving 
EGFP-LMTK2 cargoes (Figure 3b). Likewise, compared to wild-type EGFP-
LMTK2, the numbers of EGFP-LMTK2(WD1388/1389AA) anterogradely 
moving cargoes were significantly reduced (Figure 3d). Thus, the binding of 
LMTK2 to KLC1 via its WD1388/1389 motif facilitates LMTK2 transport into 
and through axons. 
 
We also calculated how siRNA loss of KLC1 and mutant 
LMTK2(WD1388/1389) affect the proportion of total moving LMTK2 cargoes 
(anterograde plus retrograde) and their anterograde velocities. Compared to 
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control siRNA, KLC1 siRNA treatment did not significantly affect either of 
these parameters. However, LMTK2(WD1388/1389) showed reduced total 
movement (p<0.001) compared to wild-type LMTK2 but this did not alter its 
velocity. These findings are in line with the LMTK2(WD1388/1389) mutant 
having a particularly potent effect on binding to KLC1.    
 
LMTK2 forms a complex with both KLC1 and p35 
LMTK2 also binds to p35 and this interaction involves amino acids within 
residues 391-632 of LMTK2 [18]. This region is located some distance from 
the KLC interaction motif (WD1388/1389) we identify above which suggests 
that LMTK2 may form a complex with both p35 and KLC1. To test this 
possibility, we first used immunoprecipitation assays to determine whether 
mutation of LMTK2(WD1388/1389) affected binding of p35 to LMTK2 in 
transfected HEK293 cells. As predicted, immunoprecipitated LMTK2 and 
LMTK2(WD1388/1389) bound equally well to p35 in these assays (Figure 4a). 
We next tested whether LMTK2 formed a complex with KLC1 and p35 again 
using immunoprecipitation assays in transfected HEK293 cells. Like many 
other non-neuronal cells lines, HEK293 cells express endogenous cdk5 but 
not p35 [19]. HA-tagged p35 was immunoprecipitated from cells co-
transfected with FLAG-KLC1 and either wild-type myc-LMTK2 or myc-
LMTK2(WD1388/1389AA) that does not bind KLC1. p35 bound to 
endogenous cdk5 and both myc-LMTK2 and myc-LMTK2(WD1388/1389AA) 
in these assays. However, KLC1 was only detected in the p35 
immunoprecipitates in the presence of wild-type LMTK2 (Figure 4b). These 
findings demonstrate that the interaction between p35 and KLC1 is dependent 
upon LMTK2. We also used PLAs to detect interactions between endogenous 
p35 and KLC1 in untreated rat cortical neurons, or in neurons treated with 
control or LMTK2 siRNAs. LMTK2 siRNAs have been characterised 
previously [27] and led to an approximate 75% reduction of LMTK2 in the 
neurons (supplementary Figure 1b). Control experiments involving omission 
of p35 or KLC1 antibodies demonstrated the specificity of these PLAs 
(Supplementary Figure 2). Robust PLA signals were detected between p35 
and KLC1 in control cells but siRNA loss of LMTK2 induced a significant 
decrease in the number of these signals (Figure 4c). Thus, LMTK2 mediates 
the formation of a complex containing both p35 and KLC1. 
 
LMTK2 is required for axonal transport of p35 
The above findings suggest that LMTK2 may function to facilitate anterograde 
axonal transport of p35 on kinesin-1-KLC1 motors. We therefore monitored 
axonal localization of transfected EGFP-p35 in untreated rat cortical neurons 
or in neurons treated with control or LMTK2 siRNAs. p35 was detected via its 
EGFP-tag and neuronal morphology determined by co-transfection with Ds-
Red as described above. In agreement with previous studies, EGFP-p35 was 
present in cell bodies and axons in control neurons [18, 20, 36]. However, 
siRNA loss of LMTK2 markedly reduced EGFP-p35 axonal levels. To quantify 
this reduction, we normalized axonal fluorescent EGFP-p35 signals to those 
in cell bodies in a manner similar to that described above for quantifying 
axonal localization of LMTK2. These studies revealed a significant reduction 
in axonal EGFP-p35 in LMTK2 siRNA knockdown neurons (Figure 5a). 
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To complement these studies, we also monitored whether siRNA loss of 
LMTK2 affected axonal transport of transfected DsRed-p35 in living rat 
cortical neurons using time-lapse microscopy. As was the case for EGFP-
LMTK2, movement of DsRed-p35 was observed in both anterograde and 
retrograde directions with a mean anterograde velocity of 0.62 +/- 0.46 Pm/s. 
This velocity was not significantly different to that observed for EGFP-LMTK2 
(see above) and is again similar to those reported for other known kinesin-
1/KLC1 cargoes such as calsyntenin-1, APP and Kidins220/ARMS [4, 50, 51]. 
However, compared to untreated or control siRNA treated neurons, siRNA 
loss of LMTK2 induced a significant reduction in anterograde movement of 
EGFP-p35 (Figure 5b). Together, these findings together demonstrate that 
LMTK2 is required for proper axonal delivery and anterograde axonal 
transport of p35. 
 
We also calculated how siRNA loss of LMTK2 affected the proportion of total 
moving p35 cargoes (anterograde plus retrograde) and their anterograde 
velocities. Compared to control siRNA, LMTK2 siRNA treatment did not 
significantly affect either of these parameters although there was a trend for a 
reduction in total movement. It is possible that increasing sample size to 
generate greater statistical power will reveal a significant affect. 
 
siRNA loss of LMTK2 also disrupts axonal transport of cdk5 
We also enquired whether siRNA loss of LMTK2 might disrupt axonal 
transport of cdk5 in a manner similar to that of its binding partner p35. To do 
so, we first monitored axonal localization of transfected HA-cdk5 in untreated 
rat cortical neurons or in neurons treated with control or LMTK2 siRNAs. 
Transfected cdk5 was detected by immunostaining for the HA-tag and 
neuronal morphology determined by co-transfection with Ds-Red as described 
above. In agreement with previous studies, HA-cdk5 was present in cell 
bodies and axons in control neurons [20, 36]. However, siRNA loss of LMTK2 
markedly reduced axonal levels of HA-cdk5. To quantify this reduction, we 
normalized axonal fluorescent HA-cdk5 signals to those in cell bodies in a 
manner similar to that described above for quantifying axonal localization of 
LMTK2 and p35. These studies revealed a significant reduction in axonal HA-
cdk5 in LMTK2 siRNA knockdown neurons (Figure 6a). 
 
We also enquired whether siRNA loss of LMTK2 affected axonal transport of 
transfected EGFP-cdk5 in living rat cortical neurons using time-lapse 
microscopy. As was the case for EGFP-LMTK2 and DsRed-p35, movement of 
EGFP-cdk5 was observed in both anterograde and retrograde directions with 
a mean anterograde velocity of 0.57 +/- 0.4 Pm/s. This velocity was not 
significantly different to those we observed for EGFP-LMTK2 or DsRed-p35 
(see above). However, compared to untreated or control siRNA treated 
neurons, siRNA loss of LMTK2 induced a significant reduction in anterograde 
movement of EGFP-p35 (Figure 5b). Together, these findings demonstrate 
that LMTK2 is also required for proper axonal delivery and anterograde 
axonal transport of cdk5. 
 
Finally, we calculated how siRNA loss of LMTK2 affected the proportion of 
total moving cdk5 cargoes (anterograde plus retrograde) and their 
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anterograde velocities. Compared to control siRNA, LMTK2 siRNA treatment 
significantly reduced both of these features (total movement reduction 
p≤0.001; velocity reduction p≤0.001). Since LMTK2 siRNA loss had only 
minor effects on total movement of p35 (see above), it is possible that these 
more potent effects on cdk5 reflect the need for additional protein-protein 
interactions for cdk5 transport. Thus, whilst p35 transport involves formation 
of a tripartite KLC1-LMTK2-p35 complex, cdk5 transport requires a quaternary 
complex of KLC1-LMTK2-p35-cdk5. 
 
LMTK2 levels are reduced in cortex but not cerebellum of Alzheimer’s disease 
patients 
Disruption to axonal transport is a major pathogenic event in Alzheimer’s 
disease [2, 5, 9, 30, 55]. Since siRNA loss of LMTK2 perturbed axonal 
transport of both p35 and cdk5, we enquired whether LMTK2 levels might be 
altered in Alzheimer’s disease. To do so, we monitored LMTK2 levels by 
immunoblotting in post mortem Alzheimer’s disease brain tissues. Details of 
these human samples are shown in Table 1; there were no significant 
differences in age or post mortem delay between the Alzheimer’s disease and 
control cases. We studied LMTK2 levels in cortex and cerebellum (affected 
and non-affected regions) in control, Braak stage III-IV (mid dementia) and 
Braak stage VI (severe dementia) cases. We normalised LMTK2 levels to the 
levels of neuron specific enolase (NSE) as described by others [21, 45]. 
Compared to controls, LMTK2 levels were reduced in cortex in both Braak 
stage III-IV and stage VI cases. By contrast, in cerebellum LMTK2 levels were 
unaffected in Braak stage III-IV but were elevated in Braak stage VI cases 
(Figure 7). These data suggest that loss of LMTK2 in dementia may contribute 
to neuronal dysfunction by disruption of axonal transport of key cargoes 
through axons. 
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Discussion 
Here we show that LMTK2 binds to kinesin-1 light chains and that this 
involves interactions between the KLC TPR domains and a C-terminal WD 
motif (WD1388/1389) in LMTK2. We also demonstrate that binding of LMTK2 
to KLCs facilitates its transport into and through axons of neurons. Thus, 
mutation of LMTK2(WD1388/1389) to inhibit binding to KLCs and siRNA loss 
of KLC1 both reduce axonal LMTK2 levels and anterograde axonal transport 
of LMTK2 in living neurons. 
 
LMTK2 also binds to the cdk5 activator protein p35 [18]. cdk5/p35 is a key 
neuronal kinase that regulates a number of fundamental cellular functions in 
both axons and synapses but the mechanisms by which it is transported to 
these locations are unknown [20, 43]. We show that LMTK2 mediates the 
formation of a KLC1-LMTK2-p35 complex and that siRNA loss of LMTK2 
perturbs axonal transport and axonal delivery of p35. We also show that 
siRNA loss of LMTK2 disrupts axonal transport of cdk5. Together, these 
findings demonstrate that LMTK2 is required for proper axonal delivery and 
anterograde axonal transport of both p35 and cdk5. 
 
siRNA knockdown of KLC1 and mutation of LMTK2(WD1388/1389) both 
reduced but did not eliminate axonal LMTK2 levels and anterograde axonal 
transport of LMTK2. The remaining transport of LMTK2 in the KLC1 siRNA 
knockdown neurons may be due to incomplete siRNA loss of KLC1 or the 
presence of KLC2 which we show also binds to LMTK2. Likewise, the 
remaining anterograde movement of mutant LMTK2(WD1388/1389AA) may 
be due to movement on KLC2 containing motors since we show that the 
LMTK2 WD mutations abrogate binding to KLC1 but only reduce binding to 
KLC2. Others have described differences in binding of WD/WE containing 
cargo proteins to KLC1 and KLC2 [10, 49]. 
 
In a similar fashion, knockdown of LMTK2 did not completely block transport 
of p35 and cdk5. This could again be a consequence of incomplete siRNA 
loss of LMTK2. Interestingly however, a further member of the LMTK family, 
LMTK1 (also known as AATYK1) has also been shown to bind to p35 so it is 
possible that LMTK1 acts to scaffold p35 to KLCs in a manner similar to that 
of LMTK2 [48]. Indeed, like LMTK2, LMTK1 contains a conserved C-terminal 
WD motif. Thus, at least two members of the LMTK family may function as 
scaffolding ligands for KLCs. 
 
Damage to p35 and disruption of cdk5/p35 activity are strongly linked to 
Alzheimer’s disease [7, 41, 43]. Moreover, abnormal cell body accumulation 
of cdk5/p35 is observed in affected regions in post mortem Alzheimer’s 
disease brains [25, 38, 39, 57]. Such accumulations are consistent with 
disruption to axonal transport of cdk5/p35. Damage to axonal transport is a 
major feature of Alzheimer’s disease [2, 5, 9, 30, 55]. Of interest therefore 
were our findings that LMTK2 levels are reduced in Alzheimer’s disease 
cortex (affected region) and that this reduction occurs in mid (Braak stage III-
IV) as well as severe (Braak stage VI) dementia cases. This loss of LMTK2 in 
Braak stage III-IV cortex suggests that it is may be an early pathogenic 
feature; early pathogenic events are generally believed to contribute most to 
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the disease process. In contrast to the Alzheimer’s disease cortex, LMTK2 
levels were elevated in Braak stage VI cerebellum. Whether this increase in 
cerebellar LMTK2 levels contributes to any protection from the 
neurodegenerative process in this brain region is not clear. Since we show 
that LMTK2 mediates axonal transport of p35 and cdk5, this loss of LMTK2 
may contribute to the cell body cdk5/p35 accumulation that has been 
described in Alzheimer’s disease [25, 38, 39, 57].  
 
Aside from binding to KLCs and p35, LMTK2 also interacts with the molecular 
motor protein myosin VI and the catalytic subunit of protein phosphatase-1 
(PP1C) [8, 16, 27, 53]. These interactions involve domains within LMTK2 that 
are distinct from the KLC WD interaction motif that we identify here. The 
LMTK2-myosin VI interaction regulates endosome trafficking and delivery of 
proteins to axonal membranes [8, 16, 24]. The interactions between cdk5/p35, 
LMTK2 and PP1 have been shown to form a signaling pathway that regulates 
the activity of glycogen synthase kinase-3E (GSK-3E) [27, 28, 32]. Like 
cdk5/p35, PP1C and GSK-3E are key signaling molecules within neurons [15, 
35]. In this pathway, cdk5/p35 phosphorylates and activates LMTK2 which in 
turn induces inhibitory phosphorylation of PP1C on threonine-320; this leads 
to increased inhibitory phosphorylation of GSK-3E on serine-9. One target of 
this signaling involves GSK-3E phosphorylation of KLC2 which causes release 
of some cargoes to inhibit their transport [27, 32]. 
 
Thus, LMTK2 is centrally placed to regulate a number of fundamental 
transport processes within axons including those driven by kinesin-1 and 
myosin VI. This regulation may be via scaffolding functions that deliver 
LMTK2 and interacting partners such as p35 and cdk5 to axons as we 
describe here, and also signaling functions involving cdk5/p35, PP1C and 
GSK-3E activities. Moreover, like cdk5/p35, both PP1 and GSK-3E are 
strongly linked to the pathogenesis of Alzheimer’s disease [6, 14, 22, 26]. The 
loss of LMTK2 that we describe in Alzheimer’s disease brains may therefore 
impact on both axonal transport and neuronal signaling functions which are all 
perturbed in dementia. Our discovery that LMTK2 is a KLC binding protein 
that facilitates axonal transport of cdk5/p35 provide the basis for a proper 
dissection of such functions. They also pave the way for further studies of 
LMTK2 in Alzheimer’s disease post mortem tissues and in transgenic mouse 
models of Alzheimer’s disease. In this context it is noteworthy that as we 
show in the post mortem human tissues, LMTK2 levels are also reduced in 
cortex and increased in cerebellum in some transgenic mouse models of 
Alzheimer’s disease [29]. Future studies could therefore include correlating 
levels of LMTK2 to those of phosphorylated Tau, Aβ, cdk5, p35 and GSK3β, 
and complementary immunohistochemical studies of LMTK2, Tau, cdk5 and 
p35. 
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Conclusions 
LMTK2 is a neuronal serine/threonine kinase that binds to the cdk5 activator 
subunit p35. Here we show that LMTK2 also binds to KLC1/2 and this 
facilitates its transport into and through axons. The interaction involves the 
TPR domains in KLC1/2 and a WD motif in the C-terminus of LMTK2. We also 
show that LMTK2 facilitates the formation of a complex containing KLC1 and 
p35 and that siRNA loss of LMTK2 disrupts axonal transport of both p35 and 
cdk5. Finally, we show that LMTK2 levels are reduced in affected cortical 
regions in post mortem Alzheimer’s disease brains. Defective cdk5/p35 
activity and damage to axonal transport are both features of Alzheimer’s 
disease. Thus, LMTK2 binds to KLC1 to direct axonal transport of p35 and its 
loss may contribute to Alzheimer’s disease. 
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List of abbreviations 
ANOVA, analysis of variance  
APP, amyloid precursor protein 
ATP, adenosine triphosphate 
Cdk5, cyclin dependent kinase-5 
EGFP, enhanced green fluorescent protein 
GSK-3E, glycogen synthase kinase-3E  
HA, hemagglutinin 
HRP, horseradish peroxidase 
IB, immunoblot 
IF, immunofluorescence 
IP, immunoprecipitation 
KLC, kinesin-1 light chains  
LMTK2, Lemur tyrosine kinase-2 
NSE, neuron specific enolase 
PLA, proximity ligation assay 
RIPA, radioimmunoprecipitation assay 
SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis 
siRNA, small interfering RNA 
TBS, Tris-HCl buffered saline 
TPR, tetratricopeptide repeat 
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Table 1  
 
Case Group Autopsy Code Sex Age 
Post-Mortem 
Delay (hrs) 
Braak 
stage 
Control A002/13 M 90 45 - 
Control A007/15 F 74 64 II 
Control A033/11 M 82 47 I 
Control A046/12 F 92 9 II 
Control A048/09 M 82 18 - 
Control A063/10 F 90 50 II 
Control A082/14 M 68 60 II 
Control A105/14 F 77 21 - 
Control A158/14 F 73 27 I 
Control A209/13 M 80 55 II-III 
Control A213/12 M 78 24 III 
Control A308/09 M 66 52 - 
Control A319/14 F 90 44 II 
Control A346/10 F 84 34 I-II 
Control A407/13 F 80 22 II 
AD Braak III-IV A037/04 F 96 39 IV 
AD Braak III-IV A041/04 F 97 67.5 III-IV 
AD Braak III-IV A065/16 M 91 48 IV 
A DBraak III-IV A067/09 F 92 19.5 III 
AD Braak III-IV A078/13 M 86 52.5 IV 
AD Braak III-IV A084/16 F 86 55.5 IV 
AD Braak III-IV A097/13 M 82 28 IV 
AD Braak III-IV A101/08 F 92 29.5 IV 
AD Braak III-IV A189/07 F 83 41.5 IV 
AD Braak III-IV A223/12 F 83 22 IV 
AD Braak III-IV  A232/16 F 95 47 IV 
AD Braak III-IV A282/11 M 93 13.5 IV 
AD Braak III-IV A374/14 M 88 79 III-IV 
AD Braak III-IV A378/14 M 98 53 IV 
AD Braak III-IV A381/16 M 84 86 IV 
AD Braak VI A008/12 M 66 41 VI 
AD Braak VI A064/16 F 93 49 VI 
AD Braak VI A087/16 F 89 38.5 VI 
AD Braak VI A100/15 F 73 30 VI 
AD Braak VI A105/13 F 81 17.5 VI 
AD Braak VI A166/12 F 86 25 VI 
AD Braak VI A171/14 M 84 67 VI 
AD Braak VI A226/16 F 69 73 VI 
AD Braak VI A258/16 M 67 39.5 VI 
AD Braak VI A289/13 M 83 22 VI 
AD Braak VI A331/15 M 86 38 VI 
AD Braak VI A342/14 F 84 27 VI 
AD Braak VI A355/14 F 79 31 VI 
AD Braak VI A377/14 F 85 79 VI 
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AD Braak VI A380/13 F 81 20 VI 
AD, Alzheimer’s disease; F, female; M, male 
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Figure Legends 
Figure 1. LMTK2 binds to both KLC1 and KLC2 via a C-terminal WD motif 
(a.a. 1388/1389). (a) LMTK2 binds to KLC1 and KLC2. HEK293 cells were 
transfected with either control empty vector (Ctrl), myc-LMTK2, FLAG-KLC1, 
FLAG-KLC2, myc-LMTK2+FLAG-KLC1 or myc-LMTK2+FLAG-KLC2. LMTK2, 
KLC1 and KLC2 were each immunoprecipitated via their epitope tags and 
bound KLC1/KLC2 or LMTK2 detected by immunoblotting. No signals for co-
immunoprecipitated proteins were obtained in control cells transfected with 
only one plasmid which demonstrates the specificity of the assays. Both 
inputs and immunoprecipitates (IP) are shown. (b and c) Mutation of 
KLC1(N302) or KLC2(N287) to leucine within their TPR domains disrupts 
binding to LMTK2. HEK293 cells were transfected with control vector, myc-
LMTK2+FLAG-KLC1, myc-LMTK2+FLAG-KLC1(N302L), myc-LMTK2+FLAG-
KLC2 or myc-LMTK2+FLAG-KLC2(N287L). myc-LMTK2 was 
immunoprecipitated via the myc-tag and bound KLC1 (b) or KLC2 (c) detected 
on immunoblots. Mutant KLC1(N302L) did not bind to LMTK2 and 
KLC2(N287L) displayed reduced binding to LMTK2. Both inputs and 
immunoprecipitates are shown. Graph in (c) shows relative levels of KLC2 
bound to LMTK2 in the immunoprecipitations following quantification of 
signals on immunoblots. Data were analysed by t-test. N=5; error bars are 
s.e.m., *p<0.05. Both inputs and immunoprecipitations (IP) are shown. (d and 
e) Mutation of LMTK2 WD(1388/1399) but not WE(477/478) to AA disrupts 
binding to KLC1 and KLC2. HEK293 cells were transfected with control 
vector, myc-LMTK2+FLAG-KLC1/KLC2, myc-LMTK2(WE477/478)+FLAG-
KLC1/KLC2 or myc-LMTK2(WD1388/1389)+KLC1/KLC2. LMTK2 was 
immunoprecipitated via its epitope tag and bound KLC1 (d) or KLC2 (e) 
detected by immunoblotting. Mutation of LMTK2 WD/AA(1388/1389) 
abolished binding of KLC1 and markedly inhibited binding of KLC2. Both 
inputs and immunoprecipitates are shown. Bar chart in (e) shows relative 
levels of KLC2 bound to LMTK2 in the immunoprecipitations following 
quantification of signals on immunoblots. Data were analysed by one-way 
analysis of variance (ANOVA) and Tukey’s post hoc test. N=3; error bars are 
s.e.m., *p<0.05.  
 
Figure 2. LMTK2 is complexed with both KLC1 and kinesin-1 and mutation of 
LMTK2(WD1388/1389) to AA disrupts this binding. (a) HEK293 cells were 
transfected with either control empty vector (Ctrl), EGFP-LMTK2+FLAG-
KLC1+myc-kinesin-1A or EGFP-LMTK2(WD1388/1389AA)+FLAG-
KLC1+myc-kinesin-1A. LMTK2 was immunoprecipitated via the EGFP-tag 
and bound KLC1 and kinesin-1 detected by immunoblotting. Both inputs and 
immunoprecipitations (IP) are shown. (b and c) Endogenous LMTK2 and 
KLC1 are complexed in HEK293 cells (b) and rat cortical neurons (c). LMTK2-
KLC1 PLAs were performed using rabbit anti-LMTK2 and goat anti-KLC1 
antibodies. Control experiments involving omission of both or each primary 
antibody are also shown. Representative phase contrast images with PLA 
signals of cells are displayed; arrows indicate PLA signals and in (c) show 
signals in axons. To facilitate viewing of signals in these phase contrast 
images, the PLAs colours were electronically changed from red to pale blue. 
Scale bars=20 Pm. Graphs show PLA signals per cell in the different 
experiments. Data were analysed by Welch’s ANOVA and Games-Howell 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 27 
post hoc test. (b) N=40-46 cells, (c) N=43-54 cells; error bars are s.e.m., 
***p<0.001. 
 
Figure 3. siRNA loss of KLC1 and mutation of LMTK2 WD(1388/1389) disrupt 
axonal transport of LMTK2. (a and b) siRNA loss of KLC1 disrupts axonal 
levels and anterograde axonal transport of LMTK2. Neurons were either 
untreated (UT) or treated with control or KLC1 siRNAs and then co-
transfected with myc-LMTK2 and DsRed to reveal neuronal architecture in (a) 
or EGFP-LMTK2 alone in (b). (a) Neurons were fixed and transfected LMTK2 
detected by immunostaining for its epitope tag. Representative images of 
neurons are displayed along with graph showing quantification of relative 
axonal LMTK2 levels. Scale bar=20 Pm. Data were analysed by Welch’s 
ANOVA and Games-Howell post hoc test; N=28-43, error bars are s.e.m., 
***p<0.001. (b) Representative kymographs showing axonal transport of 
EGFP-LMTK2 in living neurons; for clarity anterogradely moving EGFP-
LMTK2 are illustrated alongside, time=180 s. Graph shows quantification of 
anterogradely moving LMTK2 in the different siRNA treated neurons. Data 
were analysed by Welch’s ANOVA and Games-Howell post hoc test; N=15-
23, error bars are s.e.m., *p<0.05, **p<0.01. (c and d) Mutation of LMTK2 
WD(1388/1389) to AA disrupts axonal levels and anterograde axonal 
transport of LMTK2. (c) Neurons were co-transfected with DsRed and either 
myc-LMTK2 or myc-LMTK2(WD1388/1389AA) and LMTK2 detected in fixed 
cells by immunostaining for its epitope tag. Representative images of neurons 
are displayed along with graph showing quantification of relative axonal 
LMTK2 levels. Scale bar=20 Pm. Data were analysed by t-test; N=28 and 31 
neurons, error bars are s.e.m., ***p<0.001. (d) Representative kymographs 
showing axonal transport of EGFP-LMTK2 and EGFP-
LMTK2(WD1388/1389AA) in living neurons; for clarity, anterogradely moving 
EGFP-LMTK2 are illustrated alongside, time=180 s. Graph shows 
quantification of anterogradely moving LMTK2 in the different transfected 
neurons. Data were analysed by t-test; N=23-26, error bars are s.e.m., 
*p<0.05. 
 
Figure 4. LMTK2, p35 and KLC1 form a complex. (a) Mutation of 
LMTK2(WD1388/1389AA) does not affect LMTK2 binding to p35. HEK293 
cells were transfected with either control empty vector (Ctrl), myc-LMTK2, 
myc-LMTK2(WD/1388/1389AA), myc-LMTK2+p35 or myc-
LMTK2(WD1388/1389AA)+p35. LMTK2 was immunoprecipitated via the myc-
tag and bound p35 detected by immunoblotting. Both inputs and 
immunoprecipitations (IP) are shown. (b) p35 forms a complex with cdk5, 
LMTK2 and KLC1, and mutation of LMTK2(WD1388/1389AA) specifically 
disrupts KLC1 binding to the complex. HEK293 cells were transfected with 
either control empty vector (Ctrl), HA-p35+myc-LMTK2+FLAG-KLC1 or HA-
p35+myc-LMTK2(WD1388/1389AA)+FLAG-KLC1. p35 was 
immunoprecipitated via the HA-tag and bound LMTK2, KLC1 and cdk5 
detected on immunoblots. Both inputs and immunoprecipitations (IP) are 
shown. (c) LMTK2 mediates formation of a complex between KLC1 and p35 
in cortical neurons. Neurons were either untreated or treated with control or 
LMTK2 siRNAs and PLAs for KLC1 and p35 performed using goat anti-KLC1 
and rabbit anti-p35 antibodies. Neurons were also immunostained for tubulin 
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to reveal architecture. KLC1-p35 signals are markedly reduced in both cell 
bodies and axons in LMTK2 siRNA treated neurons; arrows show PLA signals 
in axons. Graph shows quantification of PLA dots in axons in the different 
treated cells. Data were analysed by Welch’s ANOVA and Games-Howell 
post hoc test; N=15-24, error bars are s.e.m., ***p<0.001. 
 
Figure 5. siRNA loss of LMTK2 reduces axonal levels and anterograde axonal 
transport of p35. (a) Neurons were either untreated (UT) or treated with 
control or LMTK2 siRNAs and then co-transfected with EGFP-p35 and DsRed 
to reveal neuronal architecture. Representative images of fixed neurons are 
displayed along with graph showing quantification of relative axonal EGFP-
p35 levels. Scale bar=20 Pm. Data were analysed by Welch’s ANOVA and 
Games-Howell post hoc test; N=30-34, error bars are s.e.m., *p<0.05, 
**p<0.01. (b) Representative kymographs showing axonal transport of DsRed-
p35 in living neurons; for clarity anterogradely moving DsRed-p35 are 
illustrated alongside, time=180 s. Graph shows quantification of anterogradely 
moving DsRed-p35 in the different treated neurons. Data were analysed by 
Welch’s ANOVA and Games-Howell post hoc test; N=17-26, error bars are 
s.e.m., *p<0.05. 
 
Figure 6. siRNA loss of LMTK2 reduces axonal levels and anterograde axonal 
transport of cdk5. (a) Neurons were either untreated (UT) or treated with 
control or LMTK2 siRNAs and then co-transfected with HA-cdk5 and DsRed 
to reveal neuronal architecture. Representative images of fixed neurons are 
displayed along with graph showing quantification of relative axonal HA-cdk5 
levels detected using the epitope tag. Scale bar=20 Pm. Data were analysed 
by Welch’s ANOVA and Games-Howell post hoc test; N=41-43, error bars are 
s.e.m., ***p<0.001. (b) Representative kymographs showing axonal transport 
of EGFP-cdk5 in living neurons; for clarity anterogradely moving EGFP-cdk5 
are illustrated alongside, time=180 s. Graph shows quantification of 
anterogradely moving EGFP-cdk5 in the different treated neurons. Data were 
analysed by Welch’s ANOVA and Games-Howell post hoc test; N=14-21, 
error bars are s.e.m., *p<0.05. 
 
Figure 7. LMTK2 levels are reduced in post mortem Alzheimer’s disease 
cortex but not cerebellum. Representative immunoblots showing LMTK2 and 
NSE levels in post mortem human control (Ctrl) and Alzheimer’s disease 
cortex and cerebellum. Graphs show quantification of LMTK2 levels in the 
different samples normalised to NSE levels. Data were analysed by one-way 
ANOVA and Holm-Sidak post hoc test, error bars are s.e.m., *p<0.05 
**p<0.01, ns not significant. 
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